Breaking News, Collaborations & Alliances

StrideBio & Takeda Enter Gene Therapy Collaboration

Will develop in vivo AAV based therapies for Friedreich's Ataxia (FA) and two additional undisclosed targets

StrideBio has entered collaboration and license agreement with Takeda Pharmaceutical to develop in vivo AAV based therapies for Friedreich’s Ataxia (FA) and two additional undisclosed targets.   These programs aim to utilize novel AAV capsids developed by StrideBio to improve potency, evade neutralizing antibodies and enhance specific tropism to tissues including the central nervous system. “We are very excited to partner with Takeda given their expertise and commitment to de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters